The global clinical trials activity saw a decrease of 8.3% in Q1 2022, when compared with the rolling average of the last four quarters (Q1 2021 to Q4 2021), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 48.1% share in Q1 2022, marking a decrease of 0.8% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 51.9% share of all the clinical trials globally in Q1 2022, marking an increase of 0.8% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q1 2022
Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2022, accounting for a 30.7% share of all trials.
This was followed by the following therapy areas: Infectious Disease with a 15.2% share, Central Nervous System with a 14.3% share, Metabolic Disorders with a 7.4% share and Cardiovascular with a 6.1% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.6% share, followed by Infectious Disease with a 17.1% share, Central Nervous System with a 14.2% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.7% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q1 2022 | Activity |
| Oncology | 27.6% | 30.7% |  |
| Infectious Disease | 17.1% | 15.2% |  |
| Central Nervous System | 14.2% | 14.3% | |
| Metabolic Disorders | 7.8% | 7.4% | |
| Cardiovascular | 7.7% | 6.1% | |
| Immunology | 5.5% | 5.7% | |
| Gastrointestinal | 6.7% | 5.3% | |
| Respiratory | 5.7% | 4.7% | |
| Dermatology | 4.6% | 4.4% | |
| Musculoskeletal Disorders | 4.1% | 4.1% | |
| Hematological Disorders | 2.7% | 3.3% | |
| Ophthalmology | 2.9% | 3.0% | |
| Genito Urinary System And Sex Hormones | 2.6% | 2.7% | |
| Genetic Disorders | 1.7% | 1.8% | |
| Women’s Health | 1.9% | 1.4% | |
| Ear Nose Throat Disorders | 1.5% | 1.3% | |
| Hormonal Disorders | 0.7% | 0.6% | |
| Male Health | 1.0% | 0.4% | |
| Mouth and Dental Disorders | 0.6% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.3% | |
| Non Malignant Disorders | 0.2% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q1 2022, accounting for a 25.5% share of all trials.
This was followed by the following therapy areas: Oncology with a 22.0% share, Infectious Disease with a 12.5% share, Cardiovascular with a 9.8% share, and Gastrointestinal with a 6.2% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 24.1%, followed by Oncology with a 23.3% share, Infectious Disease with a 15.0% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.5% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q1 2022 | Activity |
| Central Nervous System | 24.1% | 25.5% | |
| Oncology | 23.3% | 22.0% | |
| Infectious Disease | 15.0% | 12.5% | |
| Cardiovascular | 8.9% | 9.8% | |
| Gastrointestinal | 6.5% | 6.2% | |
| Metabolic Disorders | 5.3% | 6.1% | |
| Musculoskeletal Disorders | 5.0% | 5.3% | |
| Women’s Health | 4.5% | 4.2% | |
| Respiratory | 4.3% | 3.8% | |
| Immunology | 3.3% | 3.4% | |
| Hematological Disorders | 2.9% | 3.3% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.9% | |
| Dermatology | 2.9% | 2.4% | |
| Mouth and Dental Disorders | 2.5% | 2.4% | |
| Ophthalmology | 1.9% | 1.9% | |
| Ear Nose Throat Disorders | 1.1% | 1.1% | |
| Hormonal Disorders | 0.8% | 1.1% | |
| Genetic Disorders | 0.6% | 0.6% | |
| Male Health | 0.7% | 0.6% | |
| Nutritional Disorders | 0.7% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.3% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q1 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q1 2022 with a 48.0% share, compared to 54.6% in the last four quarters.
North America stood at second place with a 36.0% share in Q1 2022, over 31.3% in the last four quarters, followed by Europe with a 28.3% share in Q1 2022, as against 28.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.5% share in industry sponsored clinical trials in Q1 2022 when compared with an 83.8% average recorded in the last four quarters. Multinational trials accounted for a 14.5% share in Q1 2022, as against the four-quarter average of 16.2%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q1 2022 with a 49.8% share, over 50.8% in the last four quarters.
North America held the second position with a 20.5% share in Q1 2022, over 16.4% in the last four quarters, followed by Europe with a 15.2% share in Q1 2022, as against 14.5% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q1 2022, compared to 98.9% in the last four quarters. Multinational trials accounted for a 1.2% share in Q1 2022, as against 1.1% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q1 2022
Phase II trials outnumbered all other studies with a 39.4% share for industry sponsored trials in Q1 2022, compared to a 35.0% average in the last four quarters.
The share of Phase I trials stood at 31.6% in Q1 2022, as against the four-quarter average of 37.0%. Phase III trials held an 18.3% share in Q1 2022, registering an increase of 2.2% over the last four quarters average, followed by Phase IV trials with a 10.7% share in Q1 2022, as against the four-quarter average of 11.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 47.5% share for non-industry sponsored clinical trials in Q1 2022, compared to 41.5% in the last four quarters.
Phase IV trials stood at second place with a 20.4% share in Q1 2022, compared to 23.0% in the last four quarters. Phase I trials held a 17.2% share in Q1 2022, as against 16.0% in the last four quarters, followed by Phase III trials with a 15.0% share in Q1 2022 over a 19.4% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
